Accutar is an oncology clinical stage biotech headquartered in NJ USA, with an established pipeline and platform empowered by AI, including a variety of modalities such as chimeric degraders (TPD), small molecules, ADC / degrader antibody conjugates (DACs). Our pipeline focuses on breast cancer (3 assets), HemOnc (1 asset) and KRAS (3 assets).